<DOC>
	<DOCNO>NCT00448422</DOCNO>
	<brief_summary>The objective pivotal Phase III study investigate safety efficacy prulifloxacin versus placebo treatment patient acute bacterial gastroenteritis ( traveler 's diarrhea .</brief_summary>
	<brief_title>Safety Efficacy Prulifloxacin v Placebo Treatment Acute Gastroenteritis Adult Travelers</brief_title>
	<detailed_description>This double-blind trial compare safety efficacy prulifloxacin versus placebo adult traveler acute gastroenteritis characterize diarrhea one follow sign symptom : nausea , vomit , abdominal pain cramping , fecal urgency , moderate severe gastrointestinal-related symptom , tenesmus &lt; 72 hour duration .</detailed_description>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Prulifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>Diagnosis acute bacterial gastroenteritis Traveler industrialize country Capable give Informed Consent Fever ( &gt; 100.3 degree ) Pregnant Breast Feeding Not use adequate birth control Known Suspected ( co ) Infection nonbacterial pathogen Symptoms acute gastroenteritis &gt; 72 hour duration Bloody Diarrhea Concomitant antibacterial activity enteric bacterial pathogen History IBD Unable/Unwilling comply study protocol Greater two dos antidiarrheal medication within 24 hour &gt; 2 dos antidiarrheal medication within 24 hour Antimicrobial treatment within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Traveler 's</keyword>
	<keyword>Diarrhea</keyword>
</DOC>